Enlivex Therapeutics Ltd
Change company Symbol lookup
Select an option...
ENLV Enlivex Therapeutics Ltd
OSSIF OneSoft Solutions Inc
FAZE FaZe Holdings Inc
AYTU Aytu Biopharma Inc
WFC Wells Fargo & Co
XOM Exxon Mobil Corp
URBF Urban Barns Foods Inc
ETO Eaton Vance Tax-Advantaged Global Dividend Opportunities Fund
FMS Fresenius Medical Care AG & Co KGaA
JNJ Johnson & Johnson
Go

Health Care : Biotechnology | Small Cap Blend
Based in Israel
Company profile

Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

Postmarket

Last Trade
Delayed
$4.20
-0.06 (-1.41%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$4.26
Day's Change
-0.20 (-4.48%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
4.40
Day's Low
4.22
Volume
(Light)
Volume:
6,475

10-day average volume:
18,935
6,475

Company Profile

Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
1.17x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

September 2022
Current Month
182.7K
Previous Month
193.1K
Percent of Float
1.24%
Days to Cover
5.7383 Days

Share Information

ENLV is in a share class of common stock
Float
14.7M
Shares Outstanding
18.4M
Institutions Holding Shares
19
10.89%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Oren HershkovitzCEO
  • Shai A. NovikVice Chmn.
  • Dror Mevorach
  • Shachar ShlosbergerCFO
  • Baruch HalpertDir.

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.